We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

95 hedge funds and large institutions have $98.2M invested in Seelos Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

221% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $648K

50% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 22

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

3% more funds holding

Funds holding: 92 → 95 (+3)

9% less capital invested

Capital invested by funds: $108M → $98.2M (-$9.28M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
95
Holders Change
+3
Holders Change %
+3.26%
% of All Funds
1.66%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
19
Increased
33
Reduced
22
Closed
15
Calls
$2.08M
Puts
$648K
Net Calls
+$1.43M
Net Calls Change
+$884K

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$2.98M
2
BlackRock
BlackRock
New York
+$2.33M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$1.8M
4
Norges Bank
Norges Bank
Norway
+$1.75M
5
State Street
State Street
Massachusetts
+$894K

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$4.09M
2
GPCM
Granite Point Capital Management
Massachusetts
-$3.56M
3
Morgan Stanley
Morgan Stanley
New York
-$1.86M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.85M
5
Millennium Management
Millennium Management
New York
-$1.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$381K -$636K -74 -64%
VF
27
Virtu Financial
New York
$378K +$163K +19 +86%
Morgan Stanley
28
Morgan Stanley
New York
$325K -$1.86M -216 -86%
TAM
29
Tocqueville Asset Management
New York
$299K -$77.3K -9 -22%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$291K +$60.2K +7 +29%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$276K +$51.6K +6 +25%
Franklin Resources
32
Franklin Resources
California
$272K +$249K +29 New
1CM
33
1492 Capital Management
Wisconsin
$261K – – –
PAM
34
Panagora Asset Management
Massachusetts
$237K – – –
Goldman Sachs
35
Goldman Sachs
New York
$235K -$172K -20 -44%
Mackenzie Financial
36
Mackenzie Financial
Ontario, Canada
$215K – – –
GCP
37
GSA Capital Partners
United Kingdom
$195K +$180K +21 New
State Board of Administration of Florida Retirement System
38
State Board of Administration of Florida Retirement System
Florida
$195K +$180K +21 New
DMK
39
David M. Knott
$174K – – –
Citadel Advisors
40
Citadel Advisors
Florida
$169K +$51.6K +6 +50%
OQS
41
Occudo Quantitative Strategies
Florida
$154K -$34.4K -4 -19%
Deutsche Bank
42
Deutsche Bank
Germany
$136K -$507K -59 -80%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$134K – – –
JGC
44
J. Goldman & Co
New York
$130K -$4.09M -476 -97%
AIG
45
American International Group
New York
$130K +$25.8K +3 +27%
AI
46
AdvisorShares Investments
Maryland
$125K +$112K +13 New
APP
47
Alpha Paradigm Partners
Illinois
$125K +$112K +13 New
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$124K -$120K -14 -52%
Rafferty Asset Management
49
Rafferty Asset Management
New York
$103K +$94.5K +11 New
AllianceBernstein
50
AllianceBernstein
Tennessee
$99K – – –
1
2
3 4 5

SEEL Hedge Fund Activity: Q3 2021 in Review

95 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2021, worth a combined $98.2M — down 8.6% from $108M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new SEEL positions and 15 closed out — a net gain of 4 holders — while 33 added to existing stakes and 22 trimmed.

The largest buyer was Woodline Partners, adding an estimated $2.98M. The largest seller was J. Goldman & Co, cutting an estimated $4.09M.

  • 95 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2021, up from 92 in Q2 2021.
  • Funds reported $98.2M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2021, down 8.6% quarter-over-quarter.
  • 19 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2021 and 15 closed out, a net change of +4 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2021 was Woodline Partners, an estimated $2.98M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2021 was J. Goldman & Co, an estimated $4.09M sold.

Based on aggregated 13F filings for Q3 2021.